We recently published a list of These 10 Firms Topped Wednesday’s Trading. In this article, we are going to take a look at ...

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET. Summit ...

BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.Summit's Akeso-partnered drug, ivonescimab, works by blocking ...

Analysts at BMO Capital Markets expect Summit and Akeso’s HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Summit Therapeutics (SMMT – Research Report).

Shares of lung cancer-focused biotech Summit Therapeutics ( SMMT 10.72%) rallied 16.6% at its highs of the day before ...

Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Summit Therapeutics Inc.’s SMMT share price has surged by 5.60%, which has investors questioning if this is right time to sell.